Rhythm Pharmaceuticals Receives Japan Approval for Imcivree

08:43 AM EDT, 08/24/2026 (MT Newswires) -- Rhythm Pharmaceuticals (RYTM) said Monday that Japan's Ministry of Health, Labour and Welfare approved Imcivree to treat patients with acquired hypothalamic obesity. The company expects to launch Imcivree, the first therapy approved in Japan for acquired hypothalamic obesity, by the end of 2026, pending final pricing determination. The approval was supported by the Phase 3 TRANSCEND trial, which enrolled 142 patients and showed a statistically significant 18.8% placebo-adjusted reduction in body mass index, it added. Rhythm Pharmaceuticals shares were up 2% in premarket activity.